8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Feb 26, 2026·SEC
Material company update
Jan 12, 2026·SEC
Enovis Corporation(ENOV)Earnings, Financials & Key Ratios
ENOV•NYSE
$25.52
Price updated Jul 7, 2026
AboutEnovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.Show more
- Revenue$2.25B+6.7%
- EBITDA$276M+156.1%
- Net Income-$1.18B-43.5%
- EPS (Diluted)-20.86-39.7%
- Gross Margin59.84%+6.8%
- EBITDA Margin12.26%+152.6%
- Operating Margin-0.84%+97.7%
- Net Margin-52.69%-34.5%
- ROE-58.4%-111.7%
ENOV Price & Volume
Enovis Corporation (ENOV) stock price & volume — 10-year historical chart
Loading chart...
Integration Challenges Cloud Enovis Operational Margin Recovery
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Decelerating
Profitability:Negative
Financial:Strained
Cash Flow:Mixed
Primary Risk:High leverage and goodwill
Key Thesis Takeaways
- Enovis faces a challenging transition as it attempts to pivot from an acquisition-heavy growth phase to sustainable organic profitability.
- While the company maintains a presence in the medical device sector, persistent net losses and a significant accumulation of debt, rising from $536.4 million in 2023Q4 to $1.4 billion in 2026Q1, create substantial headwinds for shareholders.
- Investors should monitor whether the company can successfully scale its specialized sales force to improve operating margins, which recently dipped to 3.4% in 2026Q1, without further eroding its equity base.
Verdict Logic
while the forward P/E of 6.22 suggests potential value, the company's persistent net losses and high leverage, evidenced by a 15.07 debt-to-EBITDA ratio, warrant a cautious wait-and-see approach.
ENOV Growth Metrics
Enovis Corporation (ENOV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-5.52%
5 Years14.94%
3 Years12.88%
TTM5.96%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-40.49%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-43.51%
Return on Capital
10 Years-1.14%
5 Years-4.59%
3 Years-6.94%
Last Year-0.51%
ENOV Recent Earnings
Enovis Corporation (ENOV) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.89+8.5%
$0.82
Rev
$589M+3.0%
$572M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.95+17.3%
$0.81
Rev
$576M-1.2%
$583M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.75+11.9%
$0.67
Rev
$549M-6.1%
$584M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.79+6.8%
$0.74
Rev
$565M+4.8%
$539M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.89vs $0.82+8.5% | $589Mvs $572M+3.0% |
| Q1 2026 | Feb 26, 2026 | $0.95vs $0.81+17.3% | $576Mvs $583M-1.2% |
| Q4 2025 | Nov 6, 2025 | $0.75vs $0.67+11.9% | $549Mvs $584M-6.1% |
| Q3 2025 | Aug 7, 2025 | $0.79vs $0.74+6.8% | $565Mvs $539M+4.8% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Enovis Corporation (ENOV)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $25.52 | $1.47B | -1.22 | 6.66% | -52.69% | -58.4% | — | |
| $76.01 | $16.97B | 30.53 | 1.74% | 13.18% | 11.01% | — | |
| $17.72 | $2.02B | -14.52 | 8.28% | -25.66% | -50.82% | — | |
| $22.25 | $1.64B | 6.74 | 18.52% | 118.91% | 47.59% | — | |
| $105.70 | $2.41B | 41.94 | 13.53% | 24.35% | 16.19% | — | |
| $32.80 | $1.66B | -136.67 | 14.88% | -0.83% | -0.95% | — |
Compare ENOV vs Peers
Enovis Corporation (ENOV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ENOV SEC Filings & Documents
Enovis Corporation (ENOV) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ENOV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ENOV Frequently Asked Questions
Enovis Corporation (ENOV) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Enovis Corporation's revenue?
Enovis Corporation (ENOV) reported $2.28B in revenue for fiscal year 2025. This represents a 559% increase from $345.5M in 2005.
How fast is Enovis Corporation growing?
Enovis Corporation (ENOV) grew revenue by 6.7% over the past year. This is steady growth.
Is ENOV profitable?
Enovis Corporation (ENOV) reported a net loss of $1.14B for fiscal year 2025.
Dividend & Returns
What is ENOV's return on equity?
Enovis Corporation (ENOV) has a return on equity (ROE) of -58.4%. Negative ROE indicates the company is unprofitable.
What is Enovis Corporation's free cash flow?
Enovis Corporation (ENOV) generated $35.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.